Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 7.31Lincoln Pharmaceuticals demonstrates strong financial health, particularly in solvency and growth. The company efficiently manages its debts and shows good growth in revenue, operating profit, and assets. Profitability is also a notable strength, with solid returns on capital, equity, and assets, along with healthy margins. However, there are areas needing attention. The company's efficiency ratios are weak, indicating challenges in managing assets and inventory. Financial ratios also show some concerns, particularly regarding capital expenditures and earnings per share. While liquidity is reasonably managed, there is room for improvement. Overall, Lincoln Pharmaceuticals presents a mixed picture, with significant strengths offset by identifiable weaknesses in operational efficiency and financial management.
Health Score : 7.31Lincoln Pharmaceuticals demonstrates strong financial health, particularly in solvency and growth. The company efficiently manages its debts and shows good growth in revenue, operating profit, and assets. Profitability is also a notable strength, with solid returns on capital, equity, and assets, along with healthy margins. However, there are areas needing attention. The company's efficiency ratios are weak, indicating challenges in managing assets and inventory. Financial ratios also show some concerns, particularly regarding capital expenditures and earnings per share. While liquidity is reasonably managed, there is room for improvement. Overall, Lincoln Pharmaceuticals presents a mixed picture, with significant strengths offset by identifiable weaknesses in operational efficiency and financial management.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
13.89
Industry Median
32.15
Small Cap Median
31.48
P/E RATIO
13.89
P/B RATIO
1.61
Industry Median
3.71
Small Cap Median
3.46
P/S RATIO
1.82
Industry Median
2.05
Small Cap Median
1.94
Others
PEG RATIO
0.00
EV/EBITDA RATIO
9.05
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹609.65 as on Sep 1, 2026.
Growth Score : 10.00The company exhibits strong growth across various metrics, including revenue, operating profit, earnings per share, assets, and net income. This indicates a healthy expansion and effective management strategies. The consistent growth rates suggest the company is well-positioned for future success. Weighted average calculation method was used to arrive at the score.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 11.32 | 8.05 | 13.92 | 7.23 | 7.7 |
| Operating Profit Growth Rate | 10.34 | -6.25 | 11.11 | 2 | -3.92 |
| Earnings Per Share (EPS) Growth | 11.28 | 5.11 | 27.97 | -11.74 | 6.74 |
| Asset Growth Rate | 18.14 | 9.93 | 19.25 | 13.86 | 11.67 |
| Net Income Growth Rate | 11.29 | 5.8 | 27.4 | -11.83 | 7.32 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 37.27 | Overvalued | 58.00 | 6.54 | 43.00 |
| 2 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 3 | Lincoln Pharmaceuticals Ltd | 7.31 | 13.89 | Neutral | 98.00 | 43.88 | 88.00 |
| 4 | Kilitch Drugs (India) Ltd | 7.12 | 22.83 | Neutral | 37.00 | 9.27 | 30.00 |
| 5 | NGL Fine Chem Ltd | 6.98 | 34.11 | Neutral | 73.00 | 67.39 | 48.00 |
| 6 | Syncom Formulations (India) Ltd | 6.92 | 24.78 | Neutral | 77.00 | 0.81 | 76.00 |
| 7 | Sakar Healthcare Ltd | 6.89 | 70.49 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 8 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 9 | Kopran Ltd | 6.60 | 40.82 | Undervalued | 62.00 | 6.30 | 26.00 |
| 10 | SMS Lifesciences India Ltd | 6.59 | 22.25 | Undervalued | 45.00 | 58.80 | 19.00 |
| 11 | Hester Biosciences Ltd | 6.54 | 33.64 | Neutral | 87.00 | 61.24 | 57.00 |
| 12 | Sigachi Industries Ltd | 6.49 | -14.82 | Neutral | 54.00 | -2.08 | -83.00 |
| 13 | Medicamen Biotech Ltd | 5.73 | 37.61 | Neutral | 20.00 | 6.94 | 10.00 |
| 14 | Albert David Ltd | 5.63 | -333.98 | Neutral | 5.00 | -2.62 | -1.00 |
| 15 | Remus Pharmaceuticals Ltd | 5.31 | 27.61 | Neutral | 57.00 | 20.97 | 46.00 |
| 16 | Ind-Swift Laboratories Ltd | 4.95 | 77.18 | Neutral | 45.00 | 4.89 | 41.00 |
| 17 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 18 | Wanbury Ltd | 4.65 | 27.30 | Neutral | 88.00 | 15.98 | 43.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
Concall Report⬤23rd Feb 26
Q3 FY26 Earnings Conference Call
BULLISH SENTIMENT
Lincoln Pharmaceuticals Ltd. is an India-based pharmaceutical company manufacturing, marketing, and distributing a diverse range of pharmaceutical formulations. The company focuses on various therapeutic segments, both in domestic and international markets, particularly in emerging economies, with an emphasis on providing quality and affordable healthcare solutions.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Lincoln Pharmaceuticals Ltd's P/E ratio (TTM) is 13.89, compared to the industry median of 32.15 and large cap median of 31.48.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Lincoln Pharmaceuticals Ltd's P/B ratio is 1.61, compared to the industry median of 3.71 and large cap median of 3.46.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Lincoln Pharmaceuticals Ltd's P/S ratio is 1.82, compared to the industry median of 2.05 and large cap median of 1.94.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Lincoln Pharmaceuticals Ltd's PEG ratio is 1.13.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Lincoln Pharmaceuticals Ltd's EV/EBITDA ratio is 9.05.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Lincoln Pharmaceuticals Ltd's ROE is 11.61%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Lincoln Pharmaceuticals Ltd's ROA is 11.01%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Lincoln Pharmaceuticals Ltd's ROCE is 16%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Lincoln Pharmaceuticals Ltd's operating margin is 14.61%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Lincoln Pharmaceuticals Ltd's net margin is 13.11%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Lincoln Pharmaceuticals Ltd's current ratio is 3.67.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Lincoln Pharmaceuticals Ltd's debt-to-equity ratio is 0.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Lincoln Pharmaceuticals Ltd's interest coverage ratio is 117.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Lincoln Pharmaceuticals Ltd's DPS is ₹1.76.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Lincoln Pharmaceuticals Ltd's EPS is 6.74.
(Source line: "Ratios as of 26 Sept 2026, based on last traded price of ₹609.65. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1979
Headquarters: Ahmedabad, Gujarat
Core Offerings: Anti-infectives, Pain Management, Cardiovascular, Nutraceuticals, Dermatology
Stock Listing: NSE (LINCOLN), BSE (531633)
Promoter: Mahendra G. Patel Group
Founded in 1979, Lincoln Pharmaceuticals Ltd. began its journey with a commitment to producing affordable pharmaceutical formulations. Over the decades, the company has steadily expanded its manufacturing capabilities, product portfolio, and market footprint. It has successfully established a strong presence in the Indian market and significantly grown its international business, reaching over 60 countries. Continuous investment in modern, WHO-GMP certified facilities and R&D has been central to its growth strategy.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Domestic Sales | 67.4% | Operating Profit |
| Export Sales | 32.6% | Operating Profit |
Domestic Formulations: Caters to the Indian pharmaceutical market with a wide array of products across therapeutic areas such as anti-infectives, pain management, cardiovascular, dermatology, nutraceuticals, and gastrointestinal segments. Leverages an extensive distribution network.
International Business (Exports): Exports a diverse portfolio of formulations to over 60 countries, primarily in Africa, Latin America, and Southeast Asia. The company adheres to stringent international regulatory standards for its export markets.
Manufacturing Capabilities: Operates modern, WHO-GMP certified manufacturing facilities producing various dosage forms including tablets, capsules, liquids, injectables, creams, and ointments.
Mr. Mahendra G. Patel (Chairman & Managing Director). He is the founder of Lincoln Pharmaceuticals Ltd. and brings over four decades of rich experience in the pharmaceutical industry, guiding the company's strategic vision and expansion.
No major recent corporate actions on record.
The Lincoln Pharmaceuticals Ltd share price today is ₹609.65 on NSE (LINCOLN), as of 26 Sept 2026.
As of 26 Sept 2026, Lincoln Pharmaceuticals Ltd share price is ₹609.65, with previous close ₹609.65. Today's range is ₹609.65 to ₹609.65. The 52-week range is ₹440 to ₹770.
As of today, Lincoln Pharmaceuticals Ltd's market cap is ₹1,219.3 crore (Small Cap).
Lincoln Pharmaceuticals Ltd's current P/E ratio is 13.89, compared to the GENERAL & INDUSTRIAL MANUFACTURING COMPANIES sector average of 35.
Lincoln Pharmaceuticals Ltd's current P/B ratio is 1.61.
Lincoln Pharmaceuticals Ltd's current dividend yield is 0.29%. Last dividend of ₹1.50 per share was declared on Declaration: 29-May-2024.
Lincoln Pharmaceuticals Ltd's EPS (TTM) is ₹6.74.
Lincoln Pharmaceuticals Ltd. is an India-based pharmaceutical company manufacturing, marketing, and distributing a diverse range of pharmaceutical formulations. The company focuses on various therapeutic segments, both in domestic and international markets, particularly in emerging economies, with an emphasis on providing quality and affordable healthcare solutions.
Lincoln Pharmaceuticals Ltd is promoted by Mahendra G. Patel Group, holding 49.78% as of 26 Sept 2026.
Lincoln Pharmaceuticals Ltd is listed on NSE (LINCOLN) and BSE (531633). Its next quarterly results are expected on August 2024.
Adjusted Earnings Per Share (Adjusted EPS)
Capital Expenditures (CapEx)
